PD-L1 Expression and Survival among Patients with Advanced Non–Small Cell Lung Cancer Treated with Chemotherapy
Open Access
- 1 February 2016
- journal article
- research article
- Published by Elsevier BV in Translational Oncology
- Vol. 9 (1), 64-69
- https://doi.org/10.1016/j.tranon.2016.01.003
Abstract
No abstract availableThis publication has 28 references indexed in Scilit:
- PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristicsAnnals of Oncology, 2014
- PD-L1 expression in nonclear-cell renal cell carcinomaAnnals of Oncology, 2014
- Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancerBreast Cancer Research and Treatment, 2014
- Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomesEuropean Journal of Cancer, 2014
- Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinomaOncoTargets and Therapy, 2014
- Cancer statistics, 2014CA: A Cancer Journal for Clinicians, 2014
- High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturationMedical Oncology, 2010
- Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: An Individual Patient Data Meta-analysisJNCI Journal of the National Cancer Institute, 2007
- Tumor B7-H1 Is Associated with Poor Prognosis in Renal Cell Carcinoma Patients with Long-term Follow-upCancer Research, 2006
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2002